

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/922,694	08/07/2001	Atsushi Suzuki	210377US0	8724	
22850 7.	22850 7590 11/18/2003			EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EVANS, CHARESSE L		
1940 DUKE ST			ART UNIT	PAPER NUMBER	
ALEXANDRIA, VA 22314			1615	16	
			DATE MAILED: 11/18/200	. , –	

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application No.	Applicant(s)				
	09/922,694	SUZUKI ET AL.				
Office Action Summary	Examin r	Art Unit				
	Charesse L. Evans	1615				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR R THE MAILING DATE OF THIS COMMUNICATI - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ON. FR 1.136(a). In no event, however, may a reply ton. a reply within the statutory minimum of thirty (30 period will apply and will expire SIX (6) MONTHS statute, cause the application to become ABAND	be timely filed) days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. § 133).				
Status 1) ☐ Responsive to communication(s) filed on	04 August 2003					
	This action is non-final.					
Since this application is in condition for al closed in accordance with the practice un	lowance except for formal matters,					
Disposition of Claims		•				
4)⊠ Claim(s) <u>2-6,8,10-16 and 20-39</u> is/are pending in the application.						
4a) Of the above claim(s) 1,7,9 and 17-19 is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>10 and 30-36</u> is/are allowed.						
6) Claim(s) <u>2-6,8,11-16,20-29 and 37-39</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction a	and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
12)⊠ Acknowledgment is made of a claim for fo	oreign priority under 35 U.S.C. § 11	19(a)-(d) or (f).				
a)⊠ All b)□ Some * c)□ None of: 1.⊠ Certified copies of the priority docu	ments have been received.					
2. Certified copies of the priority docu3. Copies of the certified copies of the application from the International B	ments have been received in Appli priority documents have been rec ureau (PCT Rule 17.2(a)).	eived in this National Stage				
* See the attached detailed Office action for 13) Acknowledgment is made of a claim for dor since a specific reference was included in the 37 CFR 1.78.	nestic priority under 35 U.S.C. § 1	19(e) (to a provisional application)				
 a)	nestic priority under 35 U.S.C. §§	120 and/or 121 since a specific				
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-94) Information Disclosure Statement(s) (PTO-1449) Paper N	3) 5) Notice of Inform	nary (PTO-413) Paper No(s) nal Patent Application (PTO-152)				

Application/Control Number: 09/922,694

Art Unit: 1615

DETAILED ACTION

Action Summary

Acknowledgement is made of the receipt of applicant's amendment and request for reconsideration, filed August 4, 2003.

The rejection of record of claim 11 under 35 USC 112, first paragraph, is withdrawn.

The rejection of record of claims 1-6, 8 and 11-19 under 35 USC 103(a) is withdrawn.

Claims 1, 7, 9 and 17-19 have been cancelled and claims 20-39 have been added. Claims 2-6, 8, 10-16 and 20-39 are active in this action.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered

Application/Control Number: 09/922,694

Art Unit: 1615

therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6, 8, 11-16, 20-29 and 37-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abraham (XP-001148404, 1996) in view of Hsu (US 5,958,417). The claims are to a composition comprised of ferulic acid and caffeic acid, chlorogenic acid or a combination of caffeic acid and chlorogenic acid.

Abraham discloses a dietary constituent comprising a combination of chlorogenic acid, caffeic acid and ferulic acid (Table 1). These phenolic compounds occur in some of the commonly consumed vegetables, fruits and beverages (page 19, column 1).

Abraham does not expressly disclose that the referenced dietary constituents are used in the treatment of hypertension. However, Hsu (417) addresses this limitation by disclosing that the active principles, chlorogenic acid and caffeic acid, found in the herbal substance, Crataegus, are used to treat hypertension (column 2, lines 59-61).

One of ordinary skill in the art would have been motivated to combine the teachings of the cited prior art because of the need for alternatives to conventional pharmaceuticals currently used to treat hypertension, with an expectation of fewer harmful side effects.

Art Unit: 1615

Allowable Subject Matter

Claims 10 and 30-36 are allowable over the prior art.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charesse L. Evans whose telephone number is 703-308-6400. The examiner can normally be reached on Monday-Thursday 7:00a - 4:30p; Alternating Fridays 7:00a - 3:30p.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 703-308-2927. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Charesse L. Evans Examiner

Art Unit: 1615

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

November 14, 2003